These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comment on: "pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag". Srinivas NR Am J Cardiovasc Drugs; 2015 Oct; 15(5):371-2. PubMed ID: 26293236 [No Abstract] [Full Text] [Related]
6. Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study. Baldoni D; Bruderer S; Muhsen N; Dingemanse J Int J Clin Pharmacol Ther; 2015 Sep; 53(9):788-98. PubMed ID: 26152132 [TBL] [Abstract][Full Text] [Related]
7. Authors' reply to Srinivas: "pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag". Kaufmann P; Dingemanse J Am J Cardiovasc Drugs; 2015 Oct; 15(5):373-4. PubMed ID: 26293237 [No Abstract] [Full Text] [Related]
14. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension. Bruderer S; Hurst N; Remenova T; Dingemanse J Expert Opin Drug Saf; 2017 Jun; 16(6):743-751. PubMed ID: 28494686 [TBL] [Abstract][Full Text] [Related]
15. Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects. Bruderer S; Petersen-Sylla M; Boehler M; Remeňová T; Halabi A; Dingemanse J Br J Clin Pharmacol; 2017 Dec; 83(12):2778-2788. PubMed ID: 28715853 [TBL] [Abstract][Full Text] [Related]
16. Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects. Bruderer S; Okubo K; Mukai H; Mant T; Dingemanse J Clin Ther; 2016 May; 38(5):1228-1236.e1. PubMed ID: 27063071 [TBL] [Abstract][Full Text] [Related]
17. Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension. Krause A; Machacek M; Lott D; Hurst N; Bruderer S; Dingemanse J CPT Pharmacometrics Syst Pharmacol; 2017 Jul; 6(7):477-485. PubMed ID: 28556581 [TBL] [Abstract][Full Text] [Related]
18. Selexipag for the treatment of pulmonary arterial hypertension. Noel ZR; Kido K; Macaulay TE Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253 [TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194 [TBL] [Abstract][Full Text] [Related]
20. A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist. Hoch M; Darpo B; Remenova T; Stoltz R; Zhou M; Kaufmann P; Bruderer S; Dingemanse J Drug Des Devel Ther; 2015; 9():175-85. PubMed ID: 25552906 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]